RELMADA THERAPEUTICS INC's ticker is RLMD and the CUSIP is 75955J402. A total of 43 filers reported holding RELMADA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,922,246 | +36.0% | 974,082 | +11.5% | 0.23% | +40.9% |
Q2 2023 | $2,148,348 | +31.6% | 873,312 | +20.9% | 0.16% | +25.2% |
Q1 2023 | $1,632,096 | -5.8% | 722,166 | +45.5% | 0.13% | -9.7% |
Q4 2022 | $1,731,926 | -90.7% | 496,254 | -1.5% | 0.14% | -91.3% |
Q3 2022 | $18,651,000 | +95.0% | 503,801 | +0.0% | 1.67% | +94.7% |
Q2 2022 | $9,567,000 | -29.5% | 503,776 | +0.1% | 0.86% | -16.2% |
Q1 2022 | $13,578,000 | +19.7% | 503,076 | -0.1% | 1.03% | +26.2% |
Q4 2021 | $11,342,000 | -8.5% | 503,412 | +6.4% | 0.81% | -16.1% |
Q3 2021 | $12,397,000 | -14.0% | 472,974 | +5.0% | 0.97% | -12.1% |
Q2 2021 | $14,418,000 | -9.3% | 450,412 | -0.2% | 1.10% | -15.2% |
Q1 2021 | $15,894,000 | +9.7% | 451,412 | -0.0% | 1.30% | +4.2% |
Q4 2020 | $14,483,000 | -15.4% | 451,612 | -0.8% | 1.25% | -25.3% |
Q3 2020 | $17,122,000 | -15.7% | 455,137 | +0.2% | 1.67% | -22.8% |
Q2 2020 | $20,320,000 | +40.0% | 454,087 | +6.7% | 2.16% | +15.7% |
Q1 2020 | $14,516,000 | +1.4% | 425,575 | +16.0% | 1.87% | +30.2% |
Q4 2019 | $14,310,000 | – | 366,933 | – | 1.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VR Adviser, LLC | 668,440 | $21,437,000 | 3.15% |
COMMODORE CAPITAL LP | 178,565 | $5,727,000 | 3.11% |
PARSONS CAPITAL MANAGEMENT INC/RI | 451,612 | $14,483,000 | 1.25% |
ACUTA CAPITAL PARTNERS, LLC | 120,000 | $3,848,000 | 1.05% |
TANG CAPITAL MANAGEMENT LLC | 200,000 | $6,414,000 | 0.98% |
Avoro Capital Advisors LLC | 1,525,000 | $48,907,000 | 0.84% |
RTW INVESTMENTS, LP | 1,512,673 | $48,511,000 | 0.81% |
Pegasus Asset Management, Inc. | 26,958 | $865,000 | 0.47% |
HighVista Strategies LLC | 22,450 | $720,000 | 0.46% |
Spotlight Asset Group, Inc. | 22,709 | $728,000 | 0.27% |